Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies July 21, 2014
ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer’s Hallmarks in Preclinical Disease Model July 14, 2014
Anavex Announces Report Expanding Opportunity for Therapeutic Application of Anavex Compounds June 30, 2014
M1 muscarinic agonists and a multipotent activator of sigma1/M1 muscarinic receptors: Future therapeutics of Alzheimer’s disease (AD) June 10, 2014
Anavex Reports That New Data Confirms Calcium Target Over-Expression May Be Involved in Causing Alzheimer’s Disease May 22, 2014
Anavex Provides Business Update Including Clinical Trial Plans for ANAVEX PLUS in Alzheimer’s Disease May 15, 2014
